Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02933866 · ClinicalTrials.gov registry record · Phase 3
Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis
A Phase 3 study, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Phase 3
- Development phase
- 371
- Enrollment target
NCT02933866: Completed Phase 3 study, sponsored by Sun Pharmaceutical Industries.
NCT02933866 is a Phase 3 study that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 371 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (52% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02933866, a Phase 3 study, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 371 participants
- Enrollment target
Study Summary
A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site, Phase III Clinical Study to Evaluate the Efficacy and Safety of DSXS topical product in Patients with Mild to Severe Scalp Psoriasis
Primary Outcome
Clinical Success is defined by an IGA score of 0 (clear) or I (almost clear) with at least a 2 grades reduction from baseline at Day 29 ± 2
Interventions
- DRUG DSXS topical
- DRUG Vehicle topical
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 371 participants |
| Start Date | 2016-03-11 |
| Est. Completion | 2017-09-29 |
| Phase | Phase 3 |
What the finished NCT02933866 record still lists
NCT02933866 is an interventional study that assigns participants to a tested intervention. The registered 371 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (52% lower).
The record links to 0 conditions, and to 2 interventions - of which DSXS topical is the first listed.
NCT02933866 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02933866 about?
NCT02933866 is a clinical study titled "Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis". A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site, Phase III Clinical Study to Evaluate the Efficacy and Safety of DSXS topical product in Patients with Mild to Severe Scalp Psoriasis
What is the current status of trial NCT02933866?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 371 participants. The study started on 2016-03-11. Estimated completion is 2017-09-29.
What interventions are being tested in trial NCT02933866?
The interventions under investigation include: DSXS topical (DRUG), Vehicle topical (DRUG).
Who is sponsoring clinical trial NCT02933866?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02933866's enrollment target sits among peer trials
371 992nd of 2000 higher than 1,008 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05743673 · 371 participants
SHAPE Test for Preoperative Risk Stratification
- NCT05761847 · 371 participants · NA
Pediatric Medication Therapy Management Trial
- NCT04801589 · 372 participants · Phase 3
Goal-Directed Sedation in Mechanically Ventilated Infants and Children
- NCT04879329 · 372 participants · Phase 2
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI